Actinium Pharmaceuticals Investor Relations Material
Latest events
Q1 2025
9 May, 2025
Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Actinium Pharmaceuticals Inc
Access all reports
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies. These therapies are designed to deliver cancer-killing radiation to patients with high unmet medical needs, particularly in oncology and hematology. Actinium's lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal clinical trial targeting elderly patients with relapsed or refractory acute myeloid leukemia for bone marrow transplant conditioning. Actinium Pharmaceuticals Inc. is based in New York, New York, and its shares are listed on the NYSE.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
ATNM
Country
🇺🇸 United States